SODIUM IODIDE I 123

Post-LOE

sodium iodide i 123

Curium Pharma

ANDAORALCAPSULE

Approved

Feb 1989

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

SODIUM IODIDE I 123 (sodium iodide i 123) by Curium Pharma is clinical pharmacology sodium iodide i-123 is readily absorbed from the upper gastrointestinal tract. First approved in 1989.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Sodium iodide I-123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on SODIUM IODIDE I 123 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.